key: cord-0722065-aigv26u6
authors: Buchrieser, Julian; Dufloo, Jeremy; Hubert, Mathieu; Monel, Blandine; Planas, Delphine; Rajah, Maaran Michael; Planchais, Cyril; Porrot, Françoise; Guivel-Benhassine, Florence; Van der Werf, Sylvie; Casartelli, Nicoletta; Mouquet, Hugo; Bruel, Timothée; Schwartz, Olivier
title: Syncytia formation by SARS-CoV-2 infected cells
date: 2020-07-14
journal: bioRxiv
DOI: 10.1101/2020.07.14.202028
sha: eaf1545335540a010cb592f8b54e32a3077a2a83
doc_id: 722065
cord_uid: aigv26u6

Severe cases of COVID-19 are associated with extensive lung damage and the presence of infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms regulating the formation of these syncytia are not well understood. Here, we show that SARS-CoV-2 infected cells express the viral Spike protein (S) at their surface and fuse with ACE2-positive neighbouring cells. Expression of S without any other viral proteins triggers syncytia formation. Type-I interferon (IFN)-induced transmembrane proteins (IFITMs), a family of restriction factors that block the entry of many viruses, inhibit S-mediated fusion, with IFITM1 being more active than IFITM2 and IFITM3. On the contrary, the TMPRSS2 serine protease, which is known to enhance infectivity of cell-free virions, processes both S and ACE2 and increases syncytia formation by accelerating the fusion process. TMPRSS2 thwarts the antiviral effect of IFITMs. Our results show that the pathological effects of SARS-CoV-2 are modulated by cellular proteins that either inhibit or facilitate syncytia formation. One Sentence Summary Syncytia produced by SARS-CoV-2 infected cells and regulation of their formation by IFITMs and TMPRSS2.

COVID-19 consists of a spectrum of syndromes from mild, flu-like illness to severe pneumonia.

Disease severity is linked to lung epithelial destruction, resulting from both immune-mediated damages and viral cytopathic effects. SARS-CoV-2 infection of respiratory epithelial cells likely activates monocytes, macrophages, and dendritic cells, resulting in secretion of proinflammatory cytokines 1, 2 . Excessive systemic cytokine production may lead to thrombosis, hypotension, acute respiratory distress syndrome (ARDS) and fatal multi-organ failure. The innate type-I and type-III interferon (IFN) response, which normally controls viral replication is also reduced in severe cases 3, 4 .

However, prolonged IFN-production aggravates disease by impairing lung epithelial regeneration 5, 6 .

In the lung, SARS-CoV-2 infects ciliated cells in the airway, alveolar type 2 pneumocytes and epithelial progenitors among others [7] [8] [9] . SARS-CoV-2 and other coronaviruses are cytopathic [10] [11] [12] [13] [14] . The death of infected cells is also a trigger of immune activation.

receptor, angiotensin-converting enzyme 2 (ACE2), followed by S cleavage and priming by the cellular protease TMPRSS2 or other surface and endosomal proteases [15] [16] [17] . The structure of S in complex with ACE2 has been elucidated 18-20 . S consists of three S1-S2 dimers, displaying conformational changes upon virus entry leading to fusion. Besides fusion mediated by virions, S proteins present at the plasma membrane can trigger receptor-dependent syncytia formation. These syncytia have been observed in cell cultures and in tissues from individuals infected with SARS-CoV-1, MERS-CoV or SARS-CoV-2 21-28 , but they were not precisely characterized. It has been proposed that they may originate from direct infection of target cells or from the indirect immune-mediated fusion of myeloid cells. Fused pneumocytes expressing SARS-CoV-2 RNA and S proteins were observed in post-mortem lung tissues of 20 out of 41 COVID-19 patients, indicating that productive infection leads to syncytia formation, at least in critical cases 28 .

SARS-CoV2 replication is in part controlled by the innate host response, through mechanisms that are currently being unveiled. Interferon-stimulated genes (ISGs) inhibit discrete steps of the viral life cycle. At the entry level, the interferon (IFN)-Induced Transmembrane proteins (IFITM1, IFITM2, or IFITM3) block many viruses by inhibiting virus-cell fusion at hemifusion or pore formation stages 29 . IFITMs act by modifying the rigidity and/or curvature of the membranes in which they reside 29-32 .

Due to different sorting motifs, IFITM1 is mostly found at the plasma membrane, whereas IFITM2/3 accumulate in the endo-lysosomal compartment after transiting through the surface. IFITMs inhibit SARS-CoV, 229E and MERS-CoV entry, but promote infection by HCoV-OC43, a coronavirus that causes the common cold [33] [34] [35] [36] [37] [38] . IFITMs, as well as other ISGs, including LY6E and Cholesterol 25-hydrolase Here, we characterized the mechanisms of SARS-CoV-2-induced cell-cell fusion and examined how syncytia formation is impacted by IFITMs and TMPRSS2.

We first examined whether SARS-CoV-2 infected cells may form syncytia. To this aim, we derived U2OS cells stably expressing ACE2. We selected this cell line because its flat shape facilitates imaging. We generated U2OS-ACE2 cells carrying a GFP-Split complementation system 42 , in which two cells separately produce half of the reporter protein, producing GFP only upon fusion (Fig. 1A) .

These U2OS-ACE2-derived cells, that we termed "S-Fuse" cells, were exposed to various doses of SARS-CoV-2. Video-microscopy analysis showed that syncytia appeared rapidly, starting at 6h post-infection, and grew in size, as bystander cells are incorporated in fused cells (Fig. 1B ,C and movie S1). Most of the syncytia end up dying, as assessed by the acquisition of a Propidium Iodide (PI) (Fig. 1B ,C and movie S1). The extent of fusion was then quantified by measuring the GFP+ area with an automated confocal microscope. The total area of syncytia within each well correlated with the viral inoculum, indicating that the assay provides a quantitative assessment of viral infection ( Fig. 2A ). S was expressed by the syncytia, but also by single infected cells that have not yet fused, as assessed by immunofluorescence (Fig. 1D ). Flow cytometry on unpermeabilized infected cells further showed that S was present at the surface (Fig. 1E ).

We then asked whether TMPRSS2 and IFITM1, IFITM2 and IFITM3 impact syncytia formation.

We generated S-Fuse cells stably producing each of the four proteins. Their expression was verified by flow cytometry or western blotting (Fig. S1 ). We then compared their sensitivity to SARS-CoV-2 infection. The presence of TMPRSS2 increased the appearance of fused cells by 5-10 fold ( Fig. 2A) . On the contrary, IFITM1 significantly inhibited syncytia formation ( Fig. 2B and movie S1). Therefore, TMPRSS2 and IFITM1 exert opposite effects on syncytia formation. IFITM2 and 3 were poorly active ( Fig. 2B ), probably because they mostly accumulate within the endosomal compartment, which limits their ability to alter fusion events occurring at the plasma membrane. Since only 40% of each cell population expressed high levels of IFITM, as assessed by flow cytometry (Fig. S1 ) and immunofluorescence (Fig. 2C) , we asked whether IFITM+ cells were present in the syncytia. A costaining with anti-IFITM antibodies indicated that syncytia did not incorporate IFITM1+ cells present in the culture, whereas this was not the case for IFITM2 and 3 ( Fig. 2C and Fig. S3 ). Moreover, the inhibitory effect of IFITM1 on syncytia was associated a decreased number of S+ cells (Fig. 2D) .

We next assessed whether other cell types form syncytia upon SARS-CoV-2 infection. We generated and infected 293T-ACE2 and A549-ACE2 cells. We also used Vero E6 cells, which are naturally sensitive to infection. The three cell lines actively replicated the virus. Syncytia were readily detected in 293T-ACE2 but not in A549-ACE2 or Vero E6 cells (not shown). Thus, the ability to form syncytia upon SARS-CoV-2 infection is cell-type dependent.

We further characterized the mechanisms of fusion and its regulation by IFITMs and TMPRSS2.

We asked whether S alone was sufficient to trigger fusion by transfecting an expression plasmid in 293-T cells harbouring the GFP-Split system (Fig. 3A) . Many large and multinucleated GFP+ cells were detected, when ACE2 was co-expressed (Fig. 3B ). S-mediated cell fusion was significantly decreased when cells were co-transfected with flag-tagged IFITM1, 2 or 3 plasmids, compared to a control plasmid (Fig. 3B,C) . IFITM1 was slightly more inhibitory than IFITM2 and 3 in this system. The transient expression of TMPRSS2 enhanced fusion by 2.5 fold. Interestingly, when the serine protease was present, the inhibitory effect of IFITMs was no longer visible ( Fig. 3B,C) . The anti-fusogenic effect of IFITM1 varied with the amount of transfected IFITM1 plasmid, but TMPRSS2 counteracted IFITM1 at all doses (Fig. S4) . We next measured the kinetics of S-mediated cell fusion by live video-microscopy, monitoring in real-time the GFP+ area. TMPRSS2 accelerated the appearance of GFP+ cells, indicating that it increases the speed of cell-cell fusion (Movie S2 and Fig. 3D ). At 12h post-transfection, the syncytia area was already 4-fold larger than in the control condition (Fig. 3D) . A similar kinetic analysis indicated that IFITM1 strongly inhibited fusion, whereas IFITM2 and IFITM3 were less efficient (Fig.   3E ). In presence of TMPRSS2, the rapid fusion kinetics were similar with or without IFITMs (Fig. 3E ).

We next studied whether IFITMs and TMPRSS2 impact cell-cell fusion by acting on S-expressing cells ("donor cells"), on ACE2-expressing cells ("acceptor cells") or on both. To this end, we used a coculture system of 293T-GFP1-10 donor cells with 293T-GFP11 acceptor cells. IFITMs and TMPRSS2

were transfected into either donor or acceptor cells (Fig. 4A ). In the absence of TMPRSS2, IFITMs were poorly efficient when present in donor cells, but inhibited fusion in acceptor cells. As already observed, IFITM1 was more active than IFITM2 and IFITM3. When TMPRSS2 was present in donor cells, IFITMs lost their weak effect they displayed when they were also in donor cells, but retained their ability to inhibit fusion when expressed in acceptor cells (Fig. 4A ). Finally, when TMPRSS2 was expressed in acceptor cells, inhibition of fusion by IFITM was abolished regardless of their side of expression ( Fig.   4A ). Therefore, IFITMs and TMPRSS2 modulate the efficiency of fusion when present in the same cell as ACE2, rather than in the S-expressing cell.

Our observation that TMPRSS2 counteracts the inhibitory effect of IFITMs prompted us to examine whether it degrades these antiviral proteins. Flow cytometry and Western blot showed that this is not the case, since similar levels of IFITM1, IFITM2 or IFITM3 were detected in the presence or absence of the serine protease (Fig. 4B ). TMPRSS2 decreased S surface levels measured by flow cytometry with antibodies targeting the S1 and S2 domains (Fig. 4D) , as well as its processing, visualized by the disappearance of a 90 kDa product by Western Blot (Fig. 4C ). In the absence of S, TMPRSS2 also triggered ACE2 processing, a phenomenon which was not inhibited by IFITM1 (Fig. 4C ).

ACE2 cleavage by TMPRSS2 and other cellular proteases was previously reported and proposed to generate a receptor enhancing viral uptake 43-45 . Altogether, our results indicate that TMPRSS2 processes both ACE2 and S, but does not degrade IFITMs.

We report here that some SARS-CoV-2 infected cells form large syncytia in culture. This We further show that TMPRSS2 accelerates SARS-CoV-2-mediated cell-cell fusion. TMPRSS2, through its serine protease activity, is known to cleave both S and ACE2. TMPRSS2 enhances infectivity and fusogenic activity of different coronaviruses, including HCoV-229E, MERS and SARS-CoV-1 22,38,44,46-48,49 . With SARS-CoV-2, a first cleavage of S by furin at the S1/S2 site is required for subsequent cleavage by TMPRSS2 at S2' site 25 . ACE2 cleavage by TMPRSS2 at a polybasic site generates a soluble fragment of the receptor 43-45 . It has been proposed that this dual action on S and ACE2 facilitates virion uptake by target cells, through mechanisms that are not fully understood. The enhancement of syncytia formation described here with SARS-CoV-2 suggests that TMPRSS2 facilitates a step different from virion uptake. It will be worth determining which structural changes are triggered by TMPRS22 on the viral protein and its receptor, and how these changes may affect the relative affinities of the two proteins and the dynamics of the fusion process.

That TMPRSS2 counteracts the inhibitory activity of IFITMs on SARS-CoV-2-mediated syncytia formation raises interesting questions. This observation is not unprecedented, as two other coronaviruses, HCoV-229E and bat SARS-like WIV1 employ proteolytic pathways to evade IFITM restriction 38,50 . IFITM proteins modify the rigidity or the lipid content of cellular membranes to prevent fusion. How this biophysical constraint is overcome by TMPRSS2 will require further investigations.

For instance, it will be worth assessing the motility of ACE2 and S in membranes, before and during syncytia formation, and the impact of IFITM and TMPRSS2 on these processes. Determining the role of other proteins known to inhibit virion fusion, such as Ly6E and CH25H, and other proteases such as furin will provide a global overview of the mechanisms of cell-cell fusion.

An analysis of 41 post-mortem samples from individuals who died of COVID-19 demonstrated extensive alveolar damage and lung vasculature thrombosis 28 . In situ hybridization showed the presence of large multinucleated pneumocytes expressing viral RNA and proteins in half of the patients 28 . Syncytia may thus be considered as a frequent feature of severe COVID-19. It will be worth determining whether the syncytia are also generated in mild cases and whether severe or critical cases are linked to polymorphisms in IFITMs, as already reported for Flu 29,30 and in other IFN-related genes.

Our results pave the way for the future assessment of the role played by syncytia in viral persistence and dissemination, the destruction of alveolar architecture, and immune or inflammatory responses. transfected with S plasmid, with or without TMPRSS2, and analyzed 18h later. Murine polyclonal anti-S antibodies, one serum from a convalescent COVID-19 patient (sera n°111), and two monoclonal antibodies (anti-S1 and anti-S2) were tested. Data are representative of three independent experiments. pLenti6-attB-hACE2-BSD was generated by cloning hACE2 from pcDNA3.1-hACE2 into the pLenti6-H2B-mCherry. Briefly, hACE2 was PCR amplified adding SpeI, XhoI, and attB sites using forward primer (5'-TCC CTC ACT AGT ACA AGT TTG TAC AAA AAA GCA GGC TGC CAC CAT GTC AAG CTC TTC CTG GCT C -3') and reverse primer (5'-AAA AAA CTC GAG ACC ACT TTG TAC AAG AAA GCT GGG TTT AAG CGG GCG CCA CCT -3') and cloned into pLenti6-H2B-mCherry using XhoI and SpeI sites. phCMV-SARS-CoV2-S was previously described 55 . pLV-EF1α-TMPRSS2-IRES-Hygro was generated by gateway cloning of pCSDest-TMPRSS2 into pLV-EF1α-IRES-Hygro-DEST.

Cells. 293T cells, platinum-E retroviral packaging cell line, U2OS cells and derivatives were cultured in DMEM with 10% Fetal Calf Serum (FCS) and 1% Penicilline Streptomycine (PS). VeroE6 cells were maintained in DMEM with 5% FCS and 1% PS. Cell lines transduced with pQCXIP pLenti6 or pLV-IRES-Hygro derived vectors were grown with 1 µg/ml puromycin, 10 µg/ml blasticidin or 100 µg/ml hygromycin B, respectively (InvivoGen).

For lentiviral production, 293T cells were co-transfected with pLenti6 or pLV derived vectors, packaging plasmid R8-2 and VSV-G plasmid as previously described 42 . For murine retroviral vector production, the platinum-E (Cell Biolabs) retroviral packaging cell line was transfected with pQCXIP-derived plasmids. Vector containing supernatants were harvested at 36h, 48h and 72h and ultracentrifuged 1h at 4°C at 22000 g.

For lentiviral or retroviral transduction, 2x10 4 cells were resuspended in 150 µl of medium containing 5-25 µl of ultracentrifuged lentiviral or retroviral vectors. Cells were agitated 30 seconds every 5 minutes for 2h30 at 37°C in a Thermomixer. For cell lines co-expressing IFITMs and other proteins, vectors expressing the other proteins were transduced before IFITM vectors to avoid restriction of vector transduction by IFITMs. All cell lines were routinely tested for mycoplasma and found negative. To measure the extent of cell-cell fusion, the GFP area was automatically delimited, measured and then divided by the total cell area. For cell viability, nuclei were automatically counted, and the total number of nuclei per well was normalized to that of non-infected control cells. B. Quantification of syncytia expressing IFITMs. For IFITM-GFP overlap quantification, the IFITM+ area was first selected on the 647 nm channel (image 2) and the GFP positive area was quantified within the IFITM+ area (image 3). Image 4 shows the overlap area in grey for simpler visualisation. C. Quantification of infected cells expressing the S protein. The cells were stained with anti-S antibodies and the nuclei were detected with Hoechst. The S+ area was delimited (each selected object is pseudo-coloured). Nuclei present within the S+ area were scored and divided by the total number of nuclei, to calculate the number of infected cells per well. Scale bars: 100 µm. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A Dynamic Immune Response Shapes COVID-19 Progression

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

Type III interferons disrupt the lung epithelial barrier upon viral recognition

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Flow cytometry data were analyzed with FlowJo v10 software (TriStar)

Statistical analysis was conducted using GraphPad Prism 8. Statistical significance between different groups was calculated using the tests

We thank members of the Virus and Immunity Unit for discussions and help, Mauro Giacca for discussion and sharing unpublished results, Nathalie Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis, Nicolas Escriou for the kind gift of anti-SARS-CoV-2 antibodies.